Recent Finacing
Recent Raise
Cleave Therapeutics develops oral small‑molecule VCP/p97 inhibitors that modulate protein homeostasis, advancing lead candidates (CB‑5339/CB‑5083) into Phase 1 trials for solid tumors and hematologic malignancies.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Cleave Therapeutics.
